Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

UCSF, Proscia partner to study the use of AI in prostate cancer diagnosis

By Author Proscia | March 5, 2020

The University of California San Francisco (UCSF) has partnered with Proscia, a leading provider of artificial intelligence (AI) enabled digital pathology solutions, to deliver AI-enabled applications to improve the accuracy and speed of prostate cancer diagnosis.

This collaboration will first focus on validating the clinical use of digital pathology applications on prostate cancer. The research will then expand to cover other key areas of cancer diagnosis.

Our website uses cookies. By using this site, you agree to its use of cookies.